ZA958037B - Tumor rejection antigens presented by HLA-b44 molecules and uses thereof - Google Patents

Tumor rejection antigens presented by HLA-b44 molecules and uses thereof

Info

Publication number
ZA958037B
ZA958037B ZA958037A ZA958037A ZA958037B ZA 958037 B ZA958037 B ZA 958037B ZA 958037 A ZA958037 A ZA 958037A ZA 958037 A ZA958037 A ZA 958037A ZA 958037 B ZA958037 B ZA 958037B
Authority
ZA
South Africa
Prior art keywords
hla
molecules
tumor rejection
antigens presented
rejection antigens
Prior art date
Application number
ZA958037A
Inventor
Pierre Van Der Bruggen
Jean Herman
Pierre Coulie
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/373,636 external-priority patent/US5997870A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of ZA958037B publication Critical patent/ZA958037B/en

Links

ZA958037A 1995-01-17 1995-09-22 Tumor rejection antigens presented by HLA-b44 molecules and uses thereof ZA958037B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/373,636 US5997870A (en) 1994-06-03 1995-01-17 Isolated peptides which bind to HLA-B44 Molecules

Publications (1)

Publication Number Publication Date
ZA958037B true ZA958037B (en) 1996-06-06

Family

ID=23473220

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA958037A ZA958037B (en) 1995-01-17 1995-09-22 Tumor rejection antigens presented by HLA-b44 molecules and uses thereof

Country Status (1)

Country Link
ZA (1) ZA958037B (en)

Similar Documents

Publication Publication Date Title
ZA986277B (en) Tumor rejection antigens presented by HLA-B44 molecules and uses thereof
ZA961481B (en) Isolated nonapeptides presented by hla molecules and uses thereof
IL122428A0 (en) Minizymes and minribozymes and uses thereof
EP0839125A4 (en) Novel cationic lipids and the use thereof
HUP9900330A3 (en) Pyrrolopyrimidines and processes for the preparation thereof
HU9602104D0 (en) Novel medicines and their use
IL118442A0 (en) Triazolymethyl-cyclopentanols their preparation and use
IL118441A0 (en) Triazolymethyl-oxiranes their preparation and use
AU2391195A (en) Lymphocyte activation antigens and antibodies thereto
HUP0000318A3 (en) Tumor vaccine and process for the preparation thereof
ZA962280B (en) RAGE tumor rejection antigens
EP0805161A4 (en) (1-3)-beta-d-glucan-binding protein, antibody that recognizes the protein, and use of the protein and antibody
EP0761718A3 (en) Process for the preparation of poly-o-hydroxyamides and poly-o-mercaptoamides
GB9520739D0 (en) HIV specific synthetic antigens and their use
GB9516293D0 (en) Novel peptides and their use as vaccines
AU2247095A (en) Cellular immune response-specific antigens and uses therefor
AU5688596A (en) Anti-cd14 antibodies for use in the induction of il-10 secre tion
ZA96240B (en) Novel peptides their preparation and use
AU5429896A (en) Rage tumor rejection antigens
AU5014896A (en) Antibody to human betacellulin and use thereof
HUP9801330A3 (en) Novel pka-binding proteins and uses thereof
ZA96239B (en) Novel peptides their preparation and use
ZA958037B (en) Tumor rejection antigens presented by HLA-b44 molecules and uses thereof
IL122686A0 (en) Benzylhydroxylamines their preparation and use
IL118444A0 (en) Mercapto-triazolyl-silanes their preparation and use